MedTrace Logo

Integrating the Guardian Spatial Emanator Within AVENIR II

NCT07712263 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150000

Last updated 2026-07-22

No results posted yet for this study

Summary

This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger. The objective is to assess whether Guardian can be feasibly, acceptably, and effectively delivered through the same community-based platform already used for door-to-door azithromycin distribution to children 1 to 59 months of age.

Selected health center catchment areas in high-malaria-transmission settings in Niger will be randomized to integrated delivery or non-integrated delivery. The study will measure implementation outcomes including reach, coverage, acceptability, fidelity to protocol, costs, and product placement over time, and will also assess malaria-related clinic visits among children under 5 years of age using routine health facility data

Conditions

Interventions

DEVICE

Spatial Emanator

Spatial emanators are a new intervention for malaria prevention, designed to passively release volatile active ingredients that repel or incapacitate mosquitoes before they bite.

Sponsors & Collaborators

  • Centre de Recherche Médicale et Sanitaire

    collaborator OTHER

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Le Programme National de Santé Oculaire

    collaborator UNKNOWN

  • Centre de recherche et interventions en santé publique (CRISP)

    collaborator UNKNOWN

  • Ministère de la Santé Publique du Niger

    collaborator UNKNOWN

  • S.C. Johnson & Son, Inc.

    collaborator INDUSTRY

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Kieran S O'Brien, PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • Niger

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07712263 on ClinicalTrials.gov